安罗替尼三线治疗晚期卵巢癌的疗效

李成彪; 顾刚寿

doi:10.16766/j.cnki.issn.1674-4152.003071

安罗替尼三线治疗晚期卵巢癌的疗效

doi: 10.16766/j.cnki.issn.1674-4152.003071

李成彪^,,
顾刚寿

武威市人民医院肿瘤内科，甘肃武威 733000

基金项目:

甘肃省科技计划项目 20JR10RA779

详细信息

通讯作者:
李成彪, E-mail：992819206@qq.com

中图分类号: R737.31 R730.53
计量
- 文章访问数: 386
- HTML全文浏览量: 140
- PDF下载量: 6
- 被引次数: 0
出版历程
- 收稿日期: 2022-12-07
- 网络出版日期: 2023-08-28

Efficacy of anlotinib in the third-line treatment of advanced ovarian cancer

LI Chengbiao^,,
GU Gangshou

Department of Medical Oncology, Wuwei People's Hospital, Wuwei, Gansu 733000, China

摘要

摘要: 目的以安罗替尼作为晚期卵巢癌三线治疗药物，观察其在临床中的治疗效果及毒副反应，评价该治疗方式的临床价值。方法选择2020年5月1日—2022年4月30日就诊于武威市人民医院的晚期卵巢癌患者60例。采用随机数表法将患者分为对照组(30例)和治疗组(30例)，治疗组使用安罗替尼三线治疗，对照组仅给予最佳支持治疗，比较2组患者的客观缓解率(ORR)、疾病控制率(DCR)、生活质量(KPS评分)及无进展生存期(PFS)，并观察使用安罗替尼治疗的毒副反应，评价使用安罗替尼的有效性和安全性。结果治疗组患者ORR与DCR分别为26.7%(8/30)、86.7%(26/30)；对照组患者ORR与DCR分别为0、23.3%(7/30)，2组患者ORR、DCR比较差异均有统计学意义(均P＜0.05)。治疗后，治疗组患者KPS评分为(82.17±9.56)分，显著高于对照组的(75.18±9.15)分，差异有统计学意义(t=2.893, P=0.005)。治疗组部分患者用药期间出现恶心呕吐、胃肠胀气、腹泻、疲乏、高血压及食欲减退等毒副反应，但均可耐受，未影响治疗。结论安罗替尼三线治疗晚期卵巢癌，近期临床疗效较好，安全性较高。
- 卵巢癌 /
- 三线治疗 /
- 安罗替尼 /
- 疗效
Abstract: Objective To observe the clinical efficacy and toxicity of anlotinib as a third-line treatment for advanced ovarian cancer, and to evaluate the clinical value of this treatment. Methods A total of 60 patients with advanced ovarian cancer who were treated in Wuwei People's Hospital from May 1, 2020 to April 30, 2022 were selected. The patients were divided into control group (n=30) and treatment group (n=30) by random number table method. The treatment group was treated with anlotinib as third-line treatment, and the control group was only given best supportive treatment. The objective response rate (ORR), disease control rate (DCR), quality of life (KPS score) and progression-free survival (PFS) of the two groups were compared. The side effects of anlotinib treatment were observed to evaluate the efficacy and safety of anlotinib. Results The ORR and DCR of the treatment group were 26.7% (8/30) and 86.7% (26/30), respectively. The ORR and DCR of the control group were 0 and 23.3% (7/30), respectively. There were significant differences in ORR and DCR between the two groups (both P<0.05). After treatment, the KPS score of the treatment group was (82.17±9.56) points, which was significantly higher than (75.18±9.15) points of the control group, and the difference was statistically significant (t=2.893, P=0.005). Some patients in the treatment group had nausea and vomiting, flatulence, diarrhea, fatigue, hypertension and loss of appetite during the treatment, but they could be tolerated and did not affect the treatment. Conclusion Anlotinib as a third-line treatment for advanced ovarian cancer has good short-term clinical efficacy and high safety.
- Ovarian cancer /
- Third-line treatment /
- Anlotinib /
- Efficacy

HTML全文

图 1 安罗替尼三线治疗晚期卵巢癌的PFS生存曲线

Figure 1. PFS survival curve of anlotinib in a third-line treatment of advanced ovarian cancer

下载: 全尺寸图片幻灯片

表 1 2组晚期卵巢癌患者治疗前后KPS评分比较(x±s，分)

Table 1. Comparison of KPS scores before and after treatment in two groups of patients with advanced ovarian cancer (x±s, points)

组别	例数	治疗前	治疗后
对照组	30	70.52±8.31	75.18±9.15
治疗组	30	70.56±8.35	82.17±9.56
t值		0.019	2.893
P值		0.985	0.005

下载: 导出CSV

表 2 安罗替尼毒副反应分级情况

Table 2. Classification of adverse reactions of anlotinib

毒副反应	分级(例)				合计 [例(%)]
毒副反应	1级	2级	3级	4级	合计 [例(%)]
疲劳	6	1	1	0	8(26.7)
胃肠胀气	5	1	0	0	6(20.0)
高血压	7	4	0	0	11(36.7)
腹泻	4	1	0	0	5(16.7)
恶心呕吐	3	1	0	0	4(13.3)
食欲减退	4	1	1	0	6(20.0)

下载: 导出CSV

参考文献(17)

[1]	孙玉莹, 段微. 循环肿瘤DNA在卵巢癌诊断和治疗中的应用[J]. 现代妇产科进展, 2022, 31(5): 397-400. https://www.cnki.com.cn/Article/CJFDTOTAL-XDFC202205019.htm SUN Y Y, DUAN W. Application of circulating tumor DNA in the diagnosis and treatment of ovarian cancer[J]. Progress in Obstetrics and Gynecology, 2022, 31(5): 397-400. https://www.cnki.com.cn/Article/CJFDTOTAL-XDFC202205019.htm
[2]	殷爱军, 李鹏, 宋坤, 等. 安罗替尼在妇科肿瘤治疗中的现状及研究进展[J]. 现代妇产科进展, 2022, 31(5): 384-388, 393. https://www.cnki.com.cn/Article/CJFDTOTAL-XDFC202205016.htm YIN A J, LI P, SONG K, et al. Current status and research progress of anlotinib in the treatment of gynecological tumors[J]. Progress in Obstetrics and Gynecology, 2022, 31(5): 384-388, 393. https://www.cnki.com.cn/Article/CJFDTOTAL-XDFC202205016.htm
[3]	崔广华, 杨宇. 安罗替尼在晚期恶性肿瘤治疗中的研究进展[J]. 现代肿瘤医学, 2022, 30(16): 3032-3036. doi: 10.3969/j.issn.1672-4992.2022.16.034 CUI G H, YANG Y. Research progress of anlotinib in the treatment of advanced malignant tumors[J]. Journal of Modern Oncology, 2022, 30(16): 3032-3036. doi: 10.3969/j.issn.1672-4992.2022.16.034
[4]	陆富年, 张莉, 陈刚. 卵巢癌的分子诊断与靶向治疗[J]. 实用妇产科杂志, 2022, 38(8): 561-565. https://www.cnki.com.cn/Article/CJFDTOTAL-SFCZ202208001.htm LU F N, ZHANG L, CHEN G. Molecular diagnosis and targeted therapy of ovarian cancer[J]. Journal of Practical Obstetrics and Gynecology, 2022, 38(8): 561-565. https://www.cnki.com.cn/Article/CJFDTOTAL-SFCZ202208001.htm
[5]	郭钰, 徐鹏, 王蓓蒂, 等. 血清肿瘤标志物在卵巢癌诊断中的研究进展[J]. 中华全科医学, 2021, 19(8): 1362-1366. doi: 10.16766/j.cnki.issn.1674-4152.002061 GUO Y, XU P, WANG B D, et al. The research progress of serum tumor markers in the diagnosis of ovarian cancer[J]. Chinese Journal of General Practice, 2021, 19(8): 1362-1366. doi: 10.16766/j.cnki.issn.1674-4152.002061
[6]	韩婷婷, 任艳, 刘明. 经阴道彩色多普勒超声检查卵巢癌患者血流指标与肿瘤恶性度和血管新生的关系[J]. 中国肿瘤临床与康复, 2021, 28(6): 699-703. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZK202106020.htm HAN T T, REN Y, LIU M. Relationship between transvaginal color Doppler ultrasound blood flow parameter and tumor malignancy and angiogenesis in patients with ovarian cancer[J]. Chinese Journal of Clinical Oncology and Rehabilitation, 2021, 28(6): 699-703. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZK202106020.htm
[7]	王娇, 门俊芬, 梁洪陆, 等. 安罗替尼治疗二线及以上化疗失败的铂耐药卵巢癌的疗效观察[J]. 保健文汇, 2022, 23(27): 97-100. WANG J, MEN J F, LIANG H L, et al. Efficacy of anlotinib in the treatment of platinum-resistant ovarian cancer after failure of second-line chemotherapy[J]. Chinese Journal of Health Care Literature, 2020, 23(27): 97-100.
[8]	夏婷婷. 安罗替尼治疗晚期卵巢癌对血清细胞凋亡分子和血管生成因子的影响[J]. 河北医药, 2021, 43(12): 1814-1817. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYZ202112012.htm XIA T T. Effects of anlotinib in treatment of advanced ovarian cancer on serum apoptosis molecules and angiogenic factors[J]. Hebei Medical Journal, 2021, 43(12): 1814-1817. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYZ202112012.htm
[9]	周琦, 吴小华, 刘继红, 等. 卵巢恶性肿瘤诊断与治疗指南(第四版)[J]. 中国实用妇科与产科杂志, 2018, 34(7): 739-749. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGSF201811011.htm ZHOU Q, WU X H, LIU J H, et al. Guidelines to the diagnosis and treatment of malignant ovary tumors(4th edition)[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2018, 34(7): 739-749. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGSF201811011.htm
[10]	李群, 徐鹏, 熊明. 中西医结合治疗对非小细胞肺癌患者疗效、毒副作用及KPS评分的影响[J]. 现代中西医结合杂志, 2019, 28(9): 991-993. https://www.cnki.com.cn/Article/CJFDTOTAL-XDJH201909023.htm LI Q, XU P, XIONG M. To investigate the effect of integrated traditional Chinese and western medicine treatment on the efficacy, toxic side effects and KPS score of patients with non-small cell lung cancer[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2019, 28(9): 991-993. https://www.cnki.com.cn/Article/CJFDTOTAL-XDJH201909023.htm
[11]	金惠敏, 林丽红, 赵振, 等. 安罗替尼联合PD-1抑制剂后线治疗晚期上皮性卵巢癌的疗效及安全性分析[J]. 肿瘤防治研究, 2022, 49(10): 1059-1064. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLFY202210008.htm JIN H M, LIN L H, ZHAO Z, et al. Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(10): 1059-1064. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLFY202210008.htm
[12]	唐清清, 莫月媚, 苏震朝, 等. 安罗替尼联合化疗治疗晚期恶性肿瘤的临床观察[J]. 中国处方药, 2021, 19(7): 4-6. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCF202107006.htm TANG Q Q, MO Y M, SU Z C, et al. Clinical observation of anlotinib combined with chemotherapy in the treatment of advanced malignant tumor[J]. Journal of China Prescription Drug, 2021, 19(7): 4-6. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCF202107006.htm
[13]	邱天竹, 周羽璇, 陈晓锋, 等. 安罗替尼三线及以上治疗晚期妇科肿瘤的临床观察[J]. 临床肿瘤学杂志, 2020, 25(11): 1018-1021. https://www.cnki.com.cn/Article/CJFDTOTAL-LCZL202011009.htm QIU T Z, ZHOU Y X, CHEN X F, et al. Efficacy and safety of anlotinib as the third-1ine and above therapy for metastatic gynecologic cancer[J]. Chinese Clinical Oncology, 2020, 25(11): 1018-1021. https://www.cnki.com.cn/Article/CJFDTOTAL-LCZL202011009.htm
[14]	杨雪晶, 宋东, 杨晓玲, 等. 盐酸安罗替尼治疗晚期恶性肿瘤的安全性及有效性分析[J]. 肿瘤研究与临床, 2020, 32(7): 489-492. YANG X J, SONG D, YANG X L, et al. Safety and efficacy analysis of anlotinib in treatment of advanced malignant tumors[J]. Cancer Research and Clinic, 2020, 32(7): 489-492.
[15]	陈倩, 赵秧, 康马飞, 等. 安罗替尼治疗多线化疗后进展晚期卵巢癌的疗效观察[J]. 中国实用医药, 2020, 15(7): 1-3. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA202007001.htm CHEN Q, ZHAO Y, KANG M F, et al. Efficacy observation of anlotinib in the treatment of advanced ovarian cancer after multi-line chemotherapy[J]. China Practical Medicine, 2020, 15(7): 1-3. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA202007001.htm
[16]	张秀芳, 陈萍. 安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察[J]. 医学信息, 2019, 32(18): 132-134, 137. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXX201918044.htm ZHANG X F, CHEN P. Efficacy of anlotinib combined with cisplatin in the treatment of advanced ovarian cancer with malignant ascites[J]. Medical Informatics, 2019, 32(18): 132-134, 137. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXX201918044.htm
[17]	李娜, 黄琦, 张明军, 等. 安罗替尼三线治疗晚期转移性结直肠癌疗效分析[J]. 中华医学杂志, 2019, 99(36): 2844-2847. https://cdmd.cnki.com.cn/Article/CDMD-10475-1020108008.htm LI N, HUANG Q, ZHANG M J, et al. Efficacy of anlotinib as a third-line treatment for advanced metastatic colorectal cancer[J]. National Medical Journal of China, 2019, 99(36): 2844-2847. https://cdmd.cnki.com.cn/Article/CDMD-10475-1020108008.htm